# SOL Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sol-bio

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.sol-bio.com
- Total disclosed funding: $3.1M
- Latest round: Series A (Jul 14, 2021)
- Investors on record: 6

## About

Based in Seoul, South Korea, and founded by Se-Hwan Paek in 2020, SOL Bio Corp. develops exosome diagnosis platform technology that uses exosome, a substance that appears in the early-stages of cancer, to diagnose prostate cancer and early stage malignant melanoma with high accuracy of up to 95% or more. The company holds key domestic and foreign patents.

The company provides technology for early diagnosis of cancer and  manufactures ExoMAIN, a multi-cancer early detection test that uses exosome isolation kit to detect 13 major cancer types.

SOL Bio Corp. plans to focus on early commercialization of diagnostic equipment that can simultaneously diagnose three major cancers, including prostate cancer and melanoma, by securing key production facilities and live ammunition for clinical trials with this investment attraction. At the same time, it is spurring global licensing to sell diagnostic technology to overseas medical device companies. The company is also planning to be listed on KOSDAQ.

## Funding rounds

- Series A, Jul 14, 2021, $3.1M — UTC Investment, SJ Investment Partners, ES Investor, STIC Ventures
- Seed, Sep 1, 2020 — Korea Tech Incubator for Startup, Korea University Holdings
- Seed, Jun 1, 2020 — Korea University Holdings

## Investors

- Korea University Holdings (https://capitalatlas.ai/funds/korea-university-holdings) — Seed
- Korea Tech Incubator for Startup — Seed
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series A
- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series A
- ES Investor (https://capitalatlas.ai/funds/es-investor) — Series A
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series A